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Abstract
Successful vaccination against HIV should limit viral replication sufficiently to prevent the emergence of viral immune
escape mutations. Broadly directed immunity is likely to be required to limit opportunities for immune escape variants to
flourish. We studied the emergence of an SIV Gag cytotoxic T cell immune escape variant in pigtail macaques expressing the
Mane-A*10 MHC I allele using a quantitative RT-PCR to measure viral loads of escape and wild type variants. Animals
receiving whole Gag expressing vaccines completely controlled an SIVmac251 challenge, had broader CTL responses and
exhibited minimal CTL escape. In contrast, animals vaccinated with only a single CTL epitope and challenged with the same
SIVmac251 stock had high levels of viral replication and rapid CTL escape. Unvaccinated naı ¨ve animals exhibited a slower
emergence of immune escape variants. Thus narrowly directed vaccination against a single epitope resulted in rapid
immune escape and viral levels equivalent to that of naı ¨ve unvaccinated animals. These results emphasize the importance
of inducing broadly directed HIV-specific immunity that effectively quashes early viral replication and limits the generation
of immune escape variants. This has important implications for the selection of HIV vaccines for expanded human trials.
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Introduction
The HIV pandemic continues unchecked and a vaccine is
urgently needed. The lack of successful vaccination strategies
contrasts starkly with the success of antiretroviral drug therapy.
Combinations of drugs that successfully limit HIV replication do not
select for drug resistant variants and result in long-term control of
infection and near-normal life expectancy. Uniform testing and anti-
retroviral treatment ispredicted insomemodelsto ultimately control
the HIV epidemic [1]. How best to emulate such control of HIV
with immune responses induced by vaccination remains unclear [2].
Many immune escape mutations (EM), particularly those in
conserved proteins such as Gag, are likely to inflict at least some
reduction in viral replication capacity – known as a ‘‘fitness cost’’.
This is demonstrated clearly by reversion of mutations back to the
fitter wild type (WT) sequences upon transmission to new hosts not
able to mount the same immune response [3,4,5]. The
transmission of HIV strains with multiple CD8+ cytotoxic T
lymphocyte (CTL) immune escape mutations in the Gag protein
results in lower levels of viremia in recipients [6,7]. Most immune
escape mutations take some time to revert in the new hosts; this is
an advantage to the new host, as the less fit escape variants
dominate during acute infection, a time when considerable loss of
CD4 T cells can occur [8,9].
Immune escape can occur at various times after natural
infection – escape variants to strains that induce early CTL
responses will tend to appear earlier, sometimes during acute
infection [10]. Weaker, subdominant or later arising immune
responses will tend to result in delayed and slower escape [11].
The rate at which immune escape proceeds is dependent in part
on the availability of receptive target CD4 T cells [12]. Target cells
typically decrease over time, slowing down escape from later-
arising immune responses.
The prior generation of effective immune responses through
vaccination could effectively quash viral replication and limit
opportunities to escape. However, we recently postulated that if
replication is sufficiently high, pressure from vaccine-induced
response might force immune escape variants to arise early (earlier
than they might have during natural infection), reducing the
flexibility of the overall immune response [13]. This would be
particularly counter-productive if a highly dominant immune
response (to a now escaped epitope) subverted effective but
subdominant immune responses [14].
Results
We studied immune escape in 22 pigtail macaques (Macaca
nemestrina) involved in previously published SIV vaccine experi-
ments. Macaques were either vaccinated with regimens that either
expressed (a) whole SIV Gag protein [15,16], (b) or only the
KP9 Gag epitope [17] or (c) were unvaccinated. All macaques
studied expressed the Mane-A*10 MHC I allele (recently renamed
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epitope, Gag164-172 known as KP9 [19]. This KP9 epitope and
typically undergoes escape at the second amino acid (K165R
mutant) following challenge with SIVmac251 [3]. We can study
escape at this epitope in detail on serial plasma SIV RNA samples
with quantitative real time PCR (qRT-PCR) assays specific for
WT virus or the K165R escape mutant (EM) virus [20]. This
qRT-PCR assay provides a ‘‘viral load’’ for both WT and EM
variants. We applied this assay to a series of Mane-A*10+ pigtail
macaques receiving either Gag or KP9-expressing vaccines to
assess the effect of vaccine-induced immunity on the emergence of
immune escape and the outcome of SIV infection.
The 22 pigtail macaques involved in published vaccine studies
were analyzed as shown in Table 1. All were challenged
intravenously with the same stock of SIVmac251. Seventeen animals
did not receive SIV-expressing vaccines; 13 of these animals were
followed for 3 weeks (after which they were placed on ART and
entered a therapeutic vaccine protocol) and 4 animals were
followed for .20 weeks post infection. Two animals (1335, 2374)
received recombinant viral vectors (influenza A viruses) expressing
only the KP9 Gag epitope [17]. Three animals received recom-
binant viral vectors expressing SIVmac239 Gag-Pol - two animals
(5821, 5827) received a prime/boost regimen with recombinant
vaccinia and fowlpox viruses [16] and one animal (5612) received
recombinant Kunjin viruses [15]. All the Mane-A*10+ animals
from within these vaccine studies were analyzed. The viral loads,
CD4 T cell levels and KP9 specific CD8 T cell responses from
these studies have previously been reported, and the immune
escape profiles from 3 of the naı ¨ve animals and the 2 KP9-only
vaccinated animals have also been reported. Here we analyze
immune escape in all animals and compare the outcomes of
infection and timing of escape in these different vaccination
scenarios.
Outcomes of SIV challenge
Expression of the Mane-A*10 MHC class I allele by pigtail
macaques is associated with reduced viral load and reduced
disease compared to non-Mane-A*10+ pigtail macaques [21,22].
Early and complete control of SIVmac251 viremia was observed in
3 Mane-A*10+ pigtail macaques vaccinated with recombinant viral
vectors expressing whole SIV Gag (Figure 1A) [15,16,23]. In all 3
animals, SIVmac251 challenge resulted in detection of SIV RNA for
3-7 weeks at peak levels of 4.3 – 6.5 log10 copies/ml prior to
control to undetectable levels of SIV RNA using a standard viral
load assay. CD4+ T cell levels in peripheral blood dipped to 50-
70% of baseline levels during this period of acute viremia, before
returning to normal levels. There was a marked expansion of
KP9-specific CD8 T cells in the blood, identified using a Mane-
A*10/KP9 tetramer as previously described [24]. KP9-specific
CD8 T cells peaked at 8-12% shortly after acute infection. Taken
Table 1. Mane-A*10+ pigtail macaques studied for CTL escape.
Group (reference)
Animal
Number
Prior SIV Vaccines
(weeks administered)
Timing of
SIVmac251 infection
KP9 CTL epitope
sequence after infection
KP9 Gag epitope vaccinees [17] 1335 Influenza–KP9
(week 0, 4, 44, 48)
week 54 KRFGAEVVP
2374 KRFGAEVVP
Whole Gag vaccinees [15,16] 5821 VV/FPV–SIV
(week 0, 4)
week 18 KKFGAEVVP
5827 KKFGAEVVP
5612 Kunjin–SIV
(week 0, 4, 8, 18)
week 24 KRFGAEVVP
Naı ¨ve (chronic infection) [15,21] 5284 None N/A KRFGAEVVP
5424 KRFGAEVVP
5715 KRFGAEVVP
3C7D KKFGAEVVS*
Naı ¨ve (followed through acute infection
only – placed on ART at week 3) [25]
8014 None N/A KRFGAEVVP
9017 KRFGAEVVP
9176 KRFGAEVVP
9183 KKFGAEVVP
8020 KKFGAEVVP
8241 KKFGAEVVS*
8244 KRFGAEVVP
8454 KKFGAEVVP
1.3731 KRFGAEVVP
8240 KRFGAEVVP
9020 KKFGAEVVP
9021 KKFGAEVVP
9175 KRFGAEVVP
*The P172S CTL escape mutation is not detected by the qRT-PCR assay and these animals were not studied for escape rates.
doi:10.1371/journal.pone.0012774.t001
Timing of Immune Escape
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12774together, these animals represent a successful outcome of T cell
based vaccination.
In contrast, a dismal outcome was observed following SIVmac251
challenge of animals immunized with recombinant influenza A
vectors expressing only the 9 amino acid KP9 SIV Gag CD8 T
cell epitope alone [17]. Levels of viremia after acute infection were
sustained at 5–6 log10 copies/ml, approximately 1000-fold higher
than in the successfully vaccinated animals described above
(Figure 1B). A gradual and sustained loss of CD4+ T lymphocytes
resulted in both animals. This progressive SIV infection occurred
despite the marked expansion of SIV Gag KP9 specific CD8 T
cells, peaking early at 7–9% following infection.
Given these dichotomous outcomes, we then analyzed 17 naı ¨ve
Mane-A*10+ pigtail macaques infected with SIVmac251. All 17
animals had high peak viral loads and the 4 animals followed
through chronic infection maintained moderate to high viral loads
during chronic infection (4–6 log10 copies/ml, Figure 1C). All
animals showed a decline in CD4 T cells during acute infection –
this decline was not different to the vaccinated animals that also
had significant acute plasma viremia levels. Two of the 4 animals
followed through chronic infection experienced a sustained loss of
CD4 T cells. These animals were unvaccinated, and the peak
expansion of SIV Gag KP9-specific CD8 T cells in blood was
consistently slower (week 5 or later) and lower (1.5–6%) compared
to the 5 vaccinated animals above.
Generation of immune escape
The success of the vaccination strategy using whole Gag-
expressing vectors resulted in limited generation of immune escape
at the KP9 Gag CD8 T cell epitope. We first sequenced virus to
ensure that the canonical K165R escape mutant was the dominant
mutation in the animals under study – this was indeed the case for
all but 2 or the 17 control animals (3C7D and 8241) which had the
less common escape variant P172S (Table 1).
We then employed the qRT-PCR assay on animals with
K165R escape to generate serial viral load data for both WT and
the K165R KP9 EM variant. In the animals vaccinated whole
Gag-expressing vectors, the immune escape variant was not
detected at all 2 of 3 animals (Figure 2A). In one animal, the EM
variant was detected at low levels (,2.7 log10 copies/ml) at weeks
7 and 10 after challenge before disappearing.
The failed vaccination approach based on a single epitope (Gag
KP9) predictably resulted in the emergence of a CTL escape
variant, as previously reported [17]. The generation and
outgrowth of the EM virus was remarkably early and rapid, with
the EM variant observed by day 7–10 after inoculation of these
animals. The EM variant exceeded WT virus levels within 5 weeks
of SIV infection (Figure 2B).
A delayed pattern of CTL escape at the KP9 epitope is observed
in the unvaccinated SIV-infected animals. Immune escape was
substantially delayed compared to animals vaccinated against KP9
alone, with significant levels of EM virus not appearing until week
5 of infection (3–4 weeks later than the KP9 alone vaccinated
animals) and not exceeding WT virus until 7–10 weeks after
infection in the 3 animals with chronic SIV and the K165R
mutation (Figure 2C, D).
We compared the estimate of the timing of escape starting
across the vaccination groups (Fig 2E). Immune escape at the KP9
CTL epitope emerges significantly earlier in the KP9 vaccinated
animals than in naı ¨ve animals (Wilcoxon signed rank test,
Figure 1. Virologic and immunologic characteristics. Groups of animals were studied for SIV RNA levels in plasma, SIV Gag KP9-specific CD8+ T
cell levels by MHC tetramer analyses and CD4 T cell levels in peripheral blood after the same SIVmac251 challenge. Animals received either A. Vaccines
expressing whole SIV Gag, B. Vaccines only expressing the SIV Gag KP9 epitope C. Naı ¨ve unimmunized animals followed for .20 weeks or D. Naı ¨ve
unimmunized animals followed for 3 weeks.
doi:10.1371/journal.pone.0012774.g001
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EM and WT virus during early infection (at week 2 and 3). At
week 2, the relative levels of EM and WT virus are similar across
the groups, but by week 3 the levels diverge, with more EM virus
in the KP9-only vaccines (1-way ANOVA p=0.0207, Fig 2F).
We calculated the rates of immune escape across all animals and
timepoints as previously described [12] (Figure 2G). The selective
advantage of escape mutations is higher during early infection and
wanes later as a result of the decline in both CD8 T cell num-
bers and function and changes in CD4 T cell target cells [12].
Indeed, the rates of immune escape were significantly negatively
correlated with time post infection (Figure 2G; for all animals
r=20.6390, p,0.0001; for KP9-vaccinated animals r=20.749,
p=0.0149; and for naı ¨ve animals r=20.523, p=0.0018.
Spearman correlation).
Breadth of immunity after challenge
The control of viremia and prevention of immune escape at the
KP9 CD8 T cell epitope by whole Gag-expressing vaccines
suggested that immunity to other regions within Gag may have
been generated. Indeed Gag-specific T cell immunity is linked to
control of viremia both in pigtail macaques infected with
SIVmac251 [25] and humans infected with HIV-1 [26]. We
therefore went back to study non-KP9 Gag-specific CD8 T cell
responses in these animals. We constructed an overlapping Gag
15mer peptide pool that excluded the peptide containing the KP9
epitope sequence and stimulated thawed PBMC (frozen 5 weeks
after SIV challenge) to analyze the expression of intracellular
TNF-alpha, IFN-gamma and the degranulation marker CD107a
as previously described [27]. Detectable non-KP9 Gag-specific
CD8 T cell responses were found in the animals with minimal
escape at KP9 and control of viremia, but we did not detect
responses in the animals exhibiting fast escape and uncontrolled
viremia (Figure 3).
Discussion
HIV-infected subjects who spontaneously control viremia are
likely to mount effective combinations of immune responses.
Understanding and inducing such effective immunity by vaccina-
tion is a priority. We found that inducing CTL responses to a
single epitope resulted in the early selection of immune escape
species and no control of viremia, consistent with previous
macaque vaccine studies [28,29]. Inducing immune responses to
the whole Gag protein was associated with rapid control of viremia
and abrogated or limited recrudescent viremia caused by immune
escape variants. These data support the importance of a broader
base of CD8 T cell responses in facilitating control of SIV viremia
by vaccination. We speculate that if vaccination prevents early
escape at immunodominant epitopes, this may lead to sustained
virus control. The whole Gag immunization strategy could hinder
the emergence of the K165R CTL escape mutation in our model
by 3 potential mechanisms: it considerably lowers overall viral
loads, decreasing the probability of the mutation; this probability is
further lowered by the need for multiple simultaneous mutations
for the escape from the more diverse CD8 response; and the
mutations at multiple epitopes have higher chances of being
deleterious or having huge fitness costs for the EM, making the
KP9 EM subpopulation weaker [13].
Figure 2. Immune escape at the KP9 epitope. Pigtail macaques in the three vaccine groups (A. whole Gag immunized, B. KP9 immunized C.
Naı ¨ve unimmunized animals followed for .20 weeks or D. Naı ¨ve unimmunized followed for 3 weeks) were studied for viral loads of either wild type
virus or virus having the K165R escape mutation using a quantitative real time PCR with primers specific for wild type or escape mutant virus. Serial
plasma samples were studied after SIVmac251 infection. E. Minimum estimate of the timing of the start of selection for the K165R EM after SIV infection
according to vaccine modality. Each dot represents an individual animal studied. Two animals vaccinated with whole Gag expressing vaccine vectors
showed no immune escape and the timing is represented as .50 days. F. Proportion of WT virus compared to EM virus at week 2 and 3 after SIV
infection. Vaccine groups are shown by different symbols. Each dot represents an individual animal studied. G. Rates of escape plotted against time
after SIV infection. Each dot represents one animal studied at one time point.
doi:10.1371/journal.pone.0012774.g002
Figure 3. Non–KP9 Gag-specific CD8 T cell immunity. Frozen
PBMCs were studied for Gag-specific CD8 T cells expressing TNF-alpha,
IFN-gamma and CD107a five weeks after SIVmac251 infection. Panel A
shows examples of an animal receiving whole Gag immunization
compared to an animal receiving only KP9 epitope immunization. The
percentage of T cells expressing both IFN-gamma and CD107a is shown
in the upper right quadrant. Panel B shows all animals studied for both
net combined TNF-alpha and IFN-gamma as well as combined CD107a
and IFN-gamma expression. Sufficient PBMCs were available from only
one animal in the group not immunized with SIV-expressing vaccines –
this animal received Kunjin vaccines not expressing SIV antigens [15].
doi:10.1371/journal.pone.0012774.g003
Timing of Immune Escape
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12774The use of mono-epitope vaccine strategies is likely to be
particularly damaging: the recall response following viral challenge
will be primarily directed towards the escaping epitope. Subdom-
inant responses, which could otherwise help facilitate viral control
[14], are suppressed in this scenario and the progression of
infection is similar to that of control animals. This work is of
particular relevance to future vaccine approaches as the recent
unsuccessful Adenovirus type 5 vector HIV vaccine efficacy
clinical trial induced responses on average to only one Gag-specific
CD8 T cell epitope per subject [30,31]. This work predicts that
analyses of the presence and rate of CTL immune escape in this
clinical phase III trial should reveal a more rapid evolution of
escape variants in vaccine recipients compared to unvaccinated
controls expressing the same restricting MHC allele.
Several future studies should assist in refining this model of
CTL-based control of primate lentiviruses. Although we studied
22 macaques in total, only smaller subsets of these were vaccinated
and larger studies will help validate this work. Further, although all
macaques expressed the Mane-A*10 MHC I allele which restricts
the dominant KP9 Gag response, alternative MHC alleles
restricting other useful T cell responses in this outbred group
could confound our data. More extensive MHC typing found
none of the vaccinated macaques expressed the Mane-B*10 or
A*17 alleles previously shown to present the dominant KW9 or
AF9 Gag epitopes [11], as yet unknown CTL epitopes could also
facilitate viral control.
An additional area requiring further work is that different
vaccine vectors will likely play an important role in the immune
responses generated. Although we observed a similar magnitude of
the KP9 responses after challenge despite different vaccine vectors
studied, we did not examine the many other aspects of the quality
of the CD8 T cell responses generated by vaccination (e.g cytokine
expression [32], ability to rapidly kill infected cells [16,33], TCR
repertoire [34]). These may also impact upon the success of
vaccination and escape rates. Other immune responses induced by
the whole Gag-expressing vaccines (e.g. CD4 T cell responses)
could also play a role in the protective immunity observed, either
by direct effector mechanisms or by enhancing CD8 T cell
function [35]. Future studies could directly assess the impact of 1,
2, 3 or more CD8 and/or CD4 T cell epitopes expressed by the
same vaccine construct. Recently, we have constructed and tested
recombinant influenza vectors expressing 3 separate SIV CTL
epitopes, all restricted by Mane-A*10 [17,36], and can now begin
to formally address the specific breadth of CTL responses required
for adequate viral control in this model.
In summary, our data suggests that inducing broader Gag-
specific CD8 T cell immunity by vaccination will be associated
with more limited opportunities for viral escape. Inducing
responses to single immunodominant CD8 T cell epitopes could
be especially damaging when escape ensues, as subdominant
responses to the infection may be suppressed. This data has
implications for choosing HIV vaccine regimens to progress
towards efficacy studies.
Methods
Ethics Statement
Experiments on the macaques were approved by the University
of Melbourne and CSIRO livestock industries Animal Ethics
Committees, approval numbers 1065, 1139, 1164 and 1222. All
animals were cared for by dedicated trained animal technicians
and humanely euthanised before SIV disease occurred. Animals
were held according to Australian NHMRC animal welfare
guidelines in group housing with cages 2.0 m high, 3.0 m long and
1.2 m wide. An environmental enrichment strategy for animals
provided toys, treats, fresh fruits and vegetables. Specifically, there
were regular changes of equipment and toys, facilities to allow
swinging and jumping and engaging in activities from floor to
ceiling, wood chip substrates on the floor to provide opportunity
for foraging, the use of puzzle feeders, placement of food in
different locations in the enclosures and access to partially
partitioned areas within the enclosures for rest and privacy. There
was also access to mirrors and water pools. Animals were
monitored daily for health and welfare. All procedures were
carried out with sedated animals.
Animals, Vaccinations and SIV challenge
We studied 22 Mane-A*10+ pigtail macaques (Macaca nemestrina)
as shown in Table 1. Experiments on the macaques were approved
by the University of Melbourne and CSIRO livestock industries
Animal Ethics Committees. Pigtail macaques were MHC typed for
Mane-A*10 by reference strand-mediated conformational analysis
and sequence-specific primer PCR as described [19,37]. All were
challenged with the same stock of SIVmac251 IV 40 TCID50. Four
animals did not receive any SIV-expressing vaccines. Two animals
(1335, 2374) received recombinant influenza A viruses expressing
only the KP9 Gag epitope [17]. Two animals (5821, 5827)
received recombinant vaccinia and fowlpoxviruses expressing
SIVmac239 Gag-Pol [16]. One animal (5612) received recombinant
Kunjin viruses expressing SIVmac239 Gag-Pol [15]. All Mane-
A*10+ animals from within these vaccine studies were analyzed.
KP9-specific immune responses were studied on serial blood
samples using a Mane-A*10/KP9 tetramer and flow cytometry as
previously described [24]. Total SIV RNA levels (viral load) in
plasma was studied by real-time PCR as previously described [38].
CD4 T cell depletion in peripheral blood was analyzed by flow
cytometry and normalized to baseline levels as previously
described [39].
qRT-PCR for immune escape
To quantify virus levels of WT or EM quasispecies at the KP9
epitope we employed a discriminatory real-time PCR assay as
described [20,40]. Briefly, the assay uses a forward primer specific
for either wild-type sequence or specific for the nucleotide
mutation encoding the dominant K165R KP9 escape mutant.
At each timepoint after infection 10 ml of plasma RNA was to
reverse-transcribed and then amplified by qRT-PCR using either
WT or EM forward primers. A common reverse primer and
FAM-labelled DNA probe were also added for quantification
against the appropriate SIV Gag epitope RNA standards using an
Eppendorf Realplex
4 cycler. Analysis was performed using
Eppendorf Realplex software. Baselines were set 2 cycles earlier
than real reported fluorescence and threshold value was
determined by setting threshold bar within the linear data phase.
Samples amplifying after 40 cycles were regarded as negative, and
corresponded to ,1.5-Log10 SIV RNA copies/ml of plasma.
Analyses of the rate of immune escape were performed as
previously described by calculating the change in the viral species
over time [12].
Analysis of breadth of immunity
To analyze the impact of breadth of T cell immunity to Gag (i.e.
other than KP9-specific responses), we performed intracellular
cytokine staining assays for T cell activation using 5 pools of 25
overlapping 15mers peptides spanning the entire SIV Gag protein
as previously described [27]. Briefly, PBMC were stimulated for
6 hrs with the peptide pools (1 mg/ml) and then stained for T cell
surface markers (CD3, CD4, CD8), the degranulation marker
Timing of Immune Escape
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proportion of CD4+CD3+ or CD8+CD3+ T lymphocytes speci-
fically expressing IFN-gamma in responses to peptide stimulation
was analyzed by flow cytometry.
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